24 May 2022>: Review PaperHitomi Miyata 1ADE* , Yoshiaki Morita 2ADE , Anil Kumar 3DE
Ann Transplant 2022; 27:e935170
Table 1 PECOS framework.
|Parameter||Inclusion criteria||Exclusion criteria|
|* Patients were not excluded if they received a previous kidney, liver, or other organ transplant.|
** CKD was defined according to the NKF-K/DOQI and the KDIGO CKD guidelines [,]. The classification of CKD was based on GFR (iohexol clearance) or eGFR (abbreviated MDRD formula or CKD-EPI equation) stage in CKD: normal or high GFR/eGFR (≥90 mL/min/1.73 m); mild reduction in GFR/eGFR (60–89 mL/min/1.73 m); mild to moderate reduction in GFR/eGFR (45–59 mL/min/1.73 m); moderate to severe reduction in GFR/eGFR (30–44 mL/min/1.73 m); severe reduction in GFR/eGFR (15–29 mL/min/1.73 m); kidney failure (GFR/eGFR
*** Studies were included if they did not state whether or not patients were receiving maintenance dialysis prior to the current transplant, or did not specify when dialysis occurred. Where a subset of patients in a study were receiving maintenance dialysis prior to the current transplant, then the whole study was excluded, unless it was possible to exclude data for patients who received prior dialysis.
CKD – chronic kidney disease; CKD-EPI – Chronic Kidney Disease Epidemiology Collaboration; eGFR – estimated glomerular filtration rate; GFR – glomerular filtration rate; KDIGO – Kidney Disease Improving Global Outcomes; MDRD – Modification of Diet in Renal Disease; NKF-K/DOQI – National Kidney Foundation Kidney Disease Outcomes Quality Initiative; PECOS – Population, Exposure, Comparator, Outcome and Study type.